logo
logo

Concentric Analgesics Announces Completion Of $20 Million Financing And Appoints Two New Board Members As It Prepares To Initiate Registration-Enabling Phase 3 Studies For Vocacapsaicin

Jan 26, 2022•over 3 years ago

Amount Raised

$20 Million

San Francisco

Description

Concentric Analgesics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing novel, non-opioid pain therapeutics, today announced the closing of a $20 million convertible note financing from a combination of new and existing investors. In addition, the company announced the appointments of Paul R. Carter and Jonathan R. Lynch to its board of directors.

Company Information

Company

Concentric Analgesics

Location

San Francisco, California, United States

About

Concentric Analgesics is a clinical-stage, biopharmaceutical company focused on developing and commercializing novel, non-opioid pain therapeutics. The company’s portfolio of proprietary products is designed to provide long-lasting, selective pain relief after a single local administration. Vocacapsaicin is the company’s Phase 3-ready lead product candidate for postsurgical pain. Concentric has two additional active programs for osteoarthritis pain and chronic refractory pain. For more information, please visit the company’s website at: www.concentricanalgesics.com.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech